65,437 trials
Prostate Cancer
Primary: Number of Participants With > = Grade 2 Autoimmune Events or >=Toxicities at Least Possibly Related to pTVG-HP With GM-CSF Study Treatment. — 1; 0 participants
Over Active Bladder
Primary: Number of Participants With Adverse Events (AEs) by Seriousness, Severity and Relationship to Treatment — 21; 19; 0; 0 participants
Diabetes · Hypertension
Primary: Change in Systolic Blood Pressure — -8.9; -9.0 mmHg
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Dose-limiting Toxicity (DLT) (Phase I) — 1; 1 participants
Lymphoma
Primary: Overall Survival Median — 1299 days
Knee Osteoarthritis · Hip Osteoarthritis
Primary: Closure Time — 9.34; 13.57 Average time in minutes
Overactive Bladder
Primary: Evaluate Proportion of Responders Based on the Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups…
Narcolepsy
Primary: Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last…
Diabetes · Hypertension
Primary: Hemoglobin A1c — 8.4; 8.7 percentage points — p=0.15
Rheumatoid Arthritis
Primary: Change From Baseline in DAS28 Score at Week 24 — -2.12 scores on a scale
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With a Best Clinical Response of Clinical Remission (CR) — 73.7; 94.7; 63.2; 78.9 percentage of participants
Amyotrophic Lateral Sclerosis
Primary: Electrical Impedance Myography — 0.55 Coefficient of Variation
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Everolimus With Panobinostat — 10; 20 mg, orally
Insomnia
Primary: Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time — 93.38; 92.99 Percentage of Oxygen Saturation
Breast Neoplasms · Neoplasm Metastasis
Primary: Pharmacokinetics (PK) of Oral Itraconazole — 230.7; 305.8; 454.8; 501.6 ng/mL